Top Markets
Coin of the day
Hillstream BioPharma, Inc. Hillstream BioPharma, Inc.

Hillstream BioPharma, Inc.

HILS
株式のランク #37089
Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed... Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.
株価
$0.181
最終同期: 2023-10-20
時価総額
$2.03M
変化(1日)
-9.45%
変化(1年)
0.00%
US
取引 Hillstream BioPharma, Inc. (HILS)

カテゴリー

Hillstream BioPharma, Inc.(HILS)の収益
Aug 2026 時点の収益 TTM: 0
Hillstream BioPharma, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Hillstream BioPharma, Inc. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE